about
Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentRole of C-reactive protein as a biomarker for prediction of the severity of pulmonary exacerbations in patients with cystic fibrosis.Inhaled hypertonic saline in adults hospitalised for exacerbation of cystic fibrosis lung disease: a retrospective study.Toward implementation of quorum sensing autoinducers as biomarkers for infectious disease states.Airway epithelial control of Pseudomonas aeruginosa infection in cystic fibrosis.Lung infections in cystic fibrosis: deriving clinical insight from microbial complexity.Changing epidemiology and clinical issues arising in an ageing cystic fibrosis population.Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.Tobramycin Inhalation Powder™: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis.Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice.Early detection of pulmonary exacerbations in children with Cystic Fibrosis by electronic home monitoring of symptoms and lung function.Pulmonary exacerbations in cystic fibrosis and bronchiectasisAerobic fitness is associated with lower risk of hospitalization in children with cystic fibrosis.Life-space mobility is associated with frequency of hospitalization in adults with cystic fibrosis.Palivizumab, pneumococcal and influenza vaccination in cystic fibrosis
P2860
Q33824149-A0A0F77B-1461-4C28-9700-4E604B764B9BQ34320262-D3D0EE4B-4CFC-4A82-81B6-44E9C4AABBA6Q35904211-47749485-9599-4A08-93C2-63CDF4D436E5Q36704155-0A01B5FF-2F5F-46B3-B8C3-52825E91A21FQ36968815-AB33A87A-5EAE-4975-8D3B-A44A00E043EEQ37705435-B8299439-2E63-471E-943E-22A9E8CF12F8Q37809636-20AAEA78-5322-403F-A000-0EF957C2D87CQ37844338-5335BD72-09E6-424A-A9CD-034D0F8E5685Q37940005-E6010EA4-BD5E-4CC7-A225-BBCF9850493BQ38360133-012469B0-DDCC-4C86-AA0B-2768194CE542Q42011378-F5ECA1A3-4AC5-4281-9F62-BDC8B2571A67Q42733334-380839DE-FBE4-4ADE-A455-D9EF5AA14B7CQ43892015-AD0F75FC-24B2-4AFA-A228-60E3404EC9ADQ53029501-7B0B2EB3-C9F0-45CF-8786-77F601AB3073Q57026479-D12E1245-4561-4494-B710-6E54E90A23AD
P2860
description
2007 nî lūn-bûn
@nan
2007 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Exacerbations in cystic fibrosis: 2 . prevention.
@ast
Exacerbations in cystic fibrosis: 2 . prevention.
@en
type
label
Exacerbations in cystic fibrosis: 2 . prevention.
@ast
Exacerbations in cystic fibrosis: 2 . prevention.
@en
prefLabel
Exacerbations in cystic fibrosis: 2 . prevention.
@ast
Exacerbations in cystic fibrosis: 2 . prevention.
@en
P2860
P356
P1433
P1476
Exacerbations in cystic fibrosis: 2 . prevention
@en
P2093
Philip J Robinson
P2860
P304
P356
10.1136/THX.2006.060897
P407
P50
P577
2007-08-01T00:00:00Z